期刊文献+

血清HE4,CA125联合经阴道超声对卵巢癌的诊断价值 被引量:3

The Diagnostic Value of Serum HE4, CA125 and Transvaginal Sonography Combined Detection for Ovarian Cancer
原文传递
导出
摘要 目的:探讨血清人附睾蛋白4(humanepididymisprotein4,HE4)、糖类抗原125(Carbohydrateantigen125,CA125)联合经阴道超声(transvaginalsonography,TVS)对卵巢癌的诊断价值。方法:选择2013年1月~2014年12月本院确诊的卵巢病变患者500例,同期体检中心健康女性200例作为对照组,应用酶联免疫法和化学发光分析系统检测方法分别检测其血清HE4、CA125水平,并进行阴道超声检查。结果:500例卵巢病变患者经活检检查发现卵巢癌患者70例,良性卵巢疾病患者430例。卵巢癌组HE4和CA125水平均显著高于良性卵巢疾病组和健康对照组,良性卵巢疾病组HE4和CA125水平显著高于健康对照组,差异有统计学意义(P〈0.01)。血清HE4+CA125检测卵巢癌的敏感度为80.00%,特异度为95.11%;血清HE4+CA125+TVS联合检测卵巢癌的敏感度为94.29%,特异度为97.91%。HE4+CA125+TVS联合检测卵巢癌的敏感度和特异度均显著高于单项检测HE4、CA125或TVS(P〈0.05)。结论:HE4、CA125、TVS三者联合检测卵巢癌可以提高诊断的特异度和敏感度,对卵巢癌的诊断、治疗及监测具有重要意义。 Objective: To investigate the value of serum Human Epididymis protein 4(HE4), Carbohydrate antigen 125(CA125)combined transvaginal sonography(TVS) in the diagnosis of ovarian cancer. Methods: From January 2013 to December 2014 in our hospital 500 patients with ovarian disease were diagnosed as objects,, and over the same period 200 cases of healthy women were selected as a control group. Enzyme-linked immunosorbent assay and chemiluminescence detection system was used to test the serum HE4 and CA125 level respectively and TVS were checked. Results: 500 cases of ovarian disease were included 70 cases of ovarian cancer and 430 cases of patients with benign ovarian disease diagnosed by biopsy. The levels of HE4 and CA125 of ovarian cancer group were significantly higher than those of benign ovarian disease group and the healthy control group, and the HE4 and CA125 levels of benign ovarian disease group were significantly higher than those of the healthy control group, and the difference was statistically significant(P〈0.01).The sensitivity of serum HE4 combined with CA125 in ovarian cancer detection was 80.00 % and and the specificity was 95.11 %; while the sensitivity of serum HE4+CA125+TVS combined detection for ovarian cancer was 94.29 % sensitivity and the specificity was 97.91%. The sensitivity and specificity of HE4+CA125+TVS combined detection for ovarian cancer, was significantly higher than that of single detection of HE4, CA125 or TVS. Conclusions: HE4, CA125, TVS combined detection can improve the diagnostic specificity and sensitivity, which is of great importance for the diagnosis, treatment and monitoring of ovarian cancer.
出处 《现代生物医学进展》 CAS 2016年第21期4116-4119,共4页 Progress in Modern Biomedicine
基金 广西壮族自治区卫生厅自筹经费科研项目(Z2013530)
关键词 卵巢癌 人附睾蛋白4 糖类抗原125 经阴道超声 Ovarian cancer Human epididymis protein 4 Carbohydrate antigen 125 Transvaginal sonography
  • 相关文献

参考文献21

  • 1Wu R, Baker S J, Hu T C, et al. Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a raouse model of ovarian cancer [J]. The American journal of pathology, 2013, 182(4): 1391-1399.
  • 2Bojesen S E, Pooley K A, Johnatty S E, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer [J]. Nature genetics, 2013, 45 (4): 371-384.
  • 3Pharoah P D P, Tsai Y Y, Ramus S J, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer [J]. Nature genetics, 2013, 45(4): 362-370.
  • 4Pearce C L, Templeman C, Rossing M A, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies[J]. The lancet oncology, 2012, 13(4): 385-394.
  • 5Kaye S B, Lubinski J, Matulonis U, et al. Phase II, open-label, random- ized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposoraal doxombicin in patients with BRCA1 or BRCA2 mutations and recur-rent ovarian cancer [J]. Journal of Clinical Oncology, 2012, 30(4): 372-379.
  • 6Kuchenbaecker K B, Ramus S J, Tyrer J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer [J]. Na- ture genetics, 2015, 47(2): 164-171.
  • 7Hellstrom I, Hellstrom K E. fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma [J]. Expert Opinion on Med- ical Diagnostics, 2011, 5(3): 227-240.
  • 8Sarikapan W, Chan K K L, Chi An C, et al. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings[J]. Journal of Gynecologic Oncology, 2015, 26(1): 46-53.
  • 9Hamed E O, Abroad H, Sadeek O B, et al. Significance of HE4 estima- tion in comparison with CA125 in diagnosis of ovarian cancer and as- sessment of treatment response. [J]. Diagnostic Pathology, 2013, 8(1): 145-149.
  • 10Archana RS, Keith B, Robert CB, et al.The Emerging Role of HFA in the Evaluation of Advanced Epithelial Ovarian and Endometrial Car- cinomas[J]. Ontology (Williston Park), 2013, 27(6): 548-556.

同被引文献35

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部